Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Nasdaq

Published November 16, 2026 · Updated November 17, 2026

Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key ...

Read the full story at Nasdaq

Clearmind Medicine Inc., a clinical-stage biopharmaceutical company advancing non- hallucinogenic psychedelic ... press release . Clearmind is not.

Surfaced by this Google Alert

  • Psychedelic press release